Therapeutic use of anti-CS1 antibodies
View Patent ↗The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1. A monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment that binds a protein encoded by SEQ ID NO:1 and comprises the amino acid sequences of SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73 and SEQ ID NO:74.
2. The antibody or antigen binding fragment of claim 1 which is humanized.
3. The antibody or antigen binding fragment of claim 1 which is an IgG 1 .
4. The antibody or antigen binding fragment of claim 1 which comprises the amino acid sequence of SEQ ID NO:67 and the amino acid sequence of SEQ ID NO:68.
5. A conjugate compound comprising the antibody or antigen binding fragment of any one of claims 1 to 4 linked to an effector moiety and/or a detectable label.
6. The conjugate compound of claim 5 wherein the antibody or antigen binding fragment is conjugated to a detectable label.
7. The conjugate compound of claim 6 wherein the detectable label is a radioactive compound, a fluorescent compound, an enzyme, a substrate, an epitope tag, or a toxin.
8. The conjugate compound of claim 5 wherein the effector moiety is a toxin, a chemotherapeutic agent, an immune modulator, or a radioisotope.
9. A pharmaceutical composition comprising the antibody or antigen binding fragment according of any one of claims 1 to 4 .